Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

CME Credit Available: Maximum of 4.75 AMA PRA Category 1 Credits™
Release Date: June 2, 2011
Expiration Date: June 3, 2012

This activity consists of audio and visual recording of 6 live presentations with Question-and-Answer. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• Design antiretroviral strategies that consider current data on:
  
  • Initial therapy
  • The role of new and investigational drugs
  • Antiretroviral regimen failure
  • Drug-drug interactions
• Describe the incidence and management of narcotic addiction in HIV-infected patients
• Classify neurocognitive impairment in HIV-infected individuals
• Identify and discuss changes to treatment guidelines for sexually transmitted diseases and opportunistic infections
• Describe current data on investigational hepatitis C virus drugs as they impact the potential for treatment
  

CME Credit

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this internet enduring material activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Webcast Faculty

Chairs

Henry Masur, MD
Course Chair
Clinical Professor of Medicine
George Washington University School of Medicine
Washington, DC

Michael S. Saag, MD
Course Vice-Chair
Member, Board of Directors (Volunteer)
IAS–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Speakers

R. Douglas Bruce, MD, MA, MSc
Assistant Professor of Medicine and Epidemiology
Yale University School of Medicine
New Haven, Connecticut

Charles W. Flexner, MD
Professor of Medicine, Pharmacology, and International Health
Johns Hopkins University School of Medicine
Baltimore, Maryland

Jeanne Marrazzo, MD, MPH
Professor of Medicine
University of Washington
Seattle, Washington

Henry Masur, MD
Course Chair
Clinical Professor of Medicine
George Washington University
School of Medicine
Washington, DC

Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio

Victor G. Valcour, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, California



Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the IAS–USA requires all persons with control of content (ie; faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. (Updated 03/01/11)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. (Updated 03/04/11)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp (now Merck & Co, Inc), and Sanofi Pasteur. (Updated 03/01/11)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, and ViiV Healthcare. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc. (Updated 03/01/11)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, MedImmune, LLC; Merck & Co, Inc, ViiV Healthcare, and ViroStatics, and as an investigator for research study grants (to Weill Cornell) from Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. (Updated 3/4/11)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/27/11)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc. He has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc. (Updated 03/01/11)

Michael S. Saag, MD
Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 04/25/11)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, Johnson & Johnson Services, Inc, Merck & Co, Inc, Santaris Pharma, Tobira Therapeutics, and Laboratory Corporation of America. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 05/12/11)

Paul A. Volberding, MD
Dr Volberding has served as a consultant to or on scientific or clinical advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc, Merck & Co, Inc, and TaiMed Biologics. (Updated 03/01/11)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Bruce has received grants from Gilead Sciences, Inc, for pharmacokinetic research. (Updated 04/25/11)

Dr Flexner has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, Tibotec Therapeutics, and Virostatics LLC. (Updated 04/25/11)

Dr Marrazzo has served as a scientific advisor to Bayer Pharmaceuticals, Gilead Sciences, Inc, Graceway Pharmaceuticals, and Merck & Co, Inc. (Updated 04/25/11)

Dr Masur has no relevant affiliations to disclose. (Updated 04/25/11)

Dr Sherman has served as a consultant or scientific advisor to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Inc, Regulus, SciClone, Three Rivers, and Vertex Pharmaceuticals, Inc. He has served on data and safety monitoring boards and endpoint adjudication committees for MedPace, Pfizer Inc, and Tibotec Therapeutics. He received fees or royalties for written enduring materials, internet activities, and audiovisual activities from UpToDate. (Updated 04/25/11)

Dr Valcour has no relevant affiliations to disclose. (Updated 04/25/11)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Associate, has no relevant financial affiliations to disclose. (Updated 05/27/11)

Grant Support

This Webcast activity is sponsored by the IAS–USA.

Funding for this Webcast and on the live activity which this Webcast was based came from the following commercial companies:

MAJOR SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc

SUBSTANTIAL SUPPORTERS
Bristol-Myers Squibb
Tibotec Therapeutics

GENEROUS SUPPORTERS
Abbott Laboratories
ViiV Healthcare

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the IAS–USA:

IAS–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2011@iasusa.org

I have read these instructions and understand them.